DigestRedComo funciona
Red
/
Empresas
Va
No verificado

Vasomune Therapeutics, Inc.

Sobre qué escribimos

BiotecnologíaCienciaFarmacéuticaIndustriaSalud

6 Comunicados de prensa

Ver todos los comunicados de prensa
27/07/2026
Eventos
Industria
Ciencia
Medicina - Varios
Cardiología
Biotecnología
Farmacéutica
Salud
Defensa/Fuerzas Armadas
Vasomune Therapeutics to Present on Pegevongitide Therapeutic Capability at the 2026 NATO NSPA CBRN
Fuente
Vasomune Therapeutics, Inc.
Editor
Business Wire
1.00
0
21/07/2026
Ciencia
Cardiología
Biotecnología
Defensa/Fuerzas Armadas
Farmacéutica
Salud
Eventos
Industria
Vasomune Therapeutics to Present on Vascular Leak in Combat-Relevant Injury at the 2026 Military Health System Research Symposium
Fuente
Vasomune Therapeutics, Inc.
Editor
Business Wire
1.00
0
24/03/2026
Industria
Ciencia
Biotecnología
Farmacéutica
Salud
Medicina - Varios
First Patient Dosed in New Study Investigating Novel Made-In-Canada Drug Candidate to Prevent Brain Injury in Hemodialysis Patients
Fuente
Vasomune Therapeutics, Inc.
Editor
Business Wire
1.00
0
04/03/2026
Mercado laboral
Industria
Ciencia
Biotecnología
Farmacéutica
Sanidad
Salud
Higiene alimentaria
Medicina - Varios
Vasomune Therapeutics, Inc., and AnGes, Inc., Announce US FDA Clearance of Investigational New Drug (IND) Application For Pegevongitide (AV-001) Treatment in Resuscitation of Severely Burned Patients
Fuente
Vasomune Therapeutics, Inc.
Editor
Business Wire
1.00
0
03/09/2025
Ciencia
Cardiología
Biotecnología
Farmacéutica
Salud
Medicina - Varios
Mercado laboral
Industria
Health Canada Gives Green Light to New Study Investigating Novel Made-In-Canada Drug Candidate to Prevent Brain Injury in Hemodialysis Patients
Fuente
Vasomune Therapeutics, Inc.
Editor
Business Wire
1.00
0
03/12/2024
Industria
Ciencia
VIH, SIDA y enfermedades autoinmunes
Medicina - Varios
Cardiología
Biotecnología
Sanidad
Salud
Farmacéutica
Vasomune and AnGes Announce Drug Candidate AV-001 Receives Positive IDSMB Recommendation to move to the High-Dose Cohort for AV001-004 Phase 2a Study
Fuente
Vasomune Therapeutics, Inc.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0